Los Angeles – GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. illegally conspired to delay the entry to the market of a generic version of Glaxo’s epilepsy drug Lamictal in order to preserve the validity of Glaxo’s patent for the drug and allow Teva generic exclusivity, a union healthcare fund alleged in a new class action on Thursday.
The International Brotherhood of Electrical Workers Local 595 Health and Welfare Fund is seeking in its complaint in New Jersey federal court to represent a class of all those who purchased or paid for Lamictal-brand lamotrigine tablets from Glaxo or a generic version from Teva.
Glaxo has manufactured, marketed, and sold Lamictal tablets since 1994 for the treatment of medical conditions such as epilepsy, other seizure disorders, and bipolar disorder, as well as several off-label uses. Lamictal was a highly successful and profitable drug, but Glaxo’s patent for it expired in 2008.
In 2002 Teva filed abbreviated new drug applications with the U.S. Food and Drug Administration for approval to market generic versions of Glaxo’s Lamictal tablets. Glaxo then sued Teva alleging willful infringement of the Lamictal patent.
On the final day of a bench trial in the patent case, the judge issued a ruling invalidating the independent claim of the Lamictal patent, and said a ruling on its other three dependent claims would be issued shortly.
“Faced with the likelihood that its first effort to delay entry of generic versions of Lamictal would fail, Glaxo sought another vehicle to create delay and preserve its lucrative monopoly for as long as possible,” the complaint says. “With those goals in mind, in February 2005, it entered into purported settlement negotiations with Teva.”
The two companies entered into an allegedly anticompetitive settlement that same month, according to the union fund. Glaxo offered Teva a range of financial inducements in exchange for Teva’s agreement to settle the patent litigation in a way that preserved the validity of the Lamictal patent, while delaying Teva’s launch of its generic version, the fund says.
Teva agreed to delay launching its generic version of Lamictal until as late as July 2008, the expiration date of the patent. The settlement basically ignored the fact that Teva had already prevailed in its efforts to invalidate the primary patent claim, the fund says.
In exchange for the delay, Teva received the right to sell a limited quantity of generic Lamictal tablets beginning in June 2005.
“Glaxo and Teva guaranteed themselves supra-competitive revenues for several months, which resulted in anti-competitive overcharges paid by indirect purchasers of Lamictal tablets such as plaintiff and its beneficiaries,” the complaint says.
In the absence of the agreements, Teva would have brought its generic version to the market three years earlier, either because it prevailed in the Patent Litigation or chose to launch its generics “at risk,” the fund says. Other generic manufacturers would also have entered the market earlier, causing lower prices for generic Lamictal once Teva’s 180-day exclusivity period would have expired, it says.
Los Angeles – The Federal Circuit on Tuesday called for more clarity in determining the proper standards with which it should weigh claim construction decisions made in the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board, with a majority panel opinion that asked for en banc review of its own decision.
Los Angeles – Samsung Electronics Co. and Apple Inc. traded fire on Friday over whether Samsung’s allegations of misconduct on the jury foreman’s part in the trial of the pair’s epic tablet and smartphone patent infringement lawsuit merits overturning the jury’s $1 billion award and holding a new trial.
Los Angeles – TiVo Inc. told a Texas federal court Monday that its damages for its digital video recording technology patent infringement claims against Motorola Mobility Inc. and Time Warner Cable Inc. may amount to billions of dollars, due to the vast scope of the alleged infringement.
Los Angeles – A new study has revealed that 40 percent of all patent litigation in the U.S. in the past year was filed by non-practicing entities, also known as patent trolls, which amounts to double the proportion of patent cases such entities filed five years ago.
Los Angeles – A Seattle federal judge on Wednesday denied Motorola Mobility’s bid to dismiss Microsoft Inc.’s claim seeking to hold Motorola to a reasonable and non-discriminatory license agreement to be determined by the court for a set of wireless and video standards-essential patents the companies have been feuding over.
Los Angeles – The Federal Circuit said Tuesday it will convene a full en banc panel of its judges to reconsider a hotly contested three-judge panel July ruling of the appeals court upholding four financial software patents, for which the court has come under assault for allowing a too-abstract idea to receive patent protection.
Los Angeles – The Aliso Viejo, Calif.-based drug manufacturer Avanir Pharmaceuticals Inc. filed a new patent infringement lawsuit against Impax Laboratories Inc. in Delaware federal court Monday over Impax’s proposed generic version of Avanir’s neurological disorder treatment Nuedexta.
Los Angeles – The U.S. Supreme Court on Friday said it would take up a soybean farmer’s appeal of Monsanto Co.’s successful patent infringement claims against him over his use of second-generation patented herbicide-resistant seeds.
Los Angeles – Samsung Electronics Co. on Tuesday accused the foreman of the jury that handed down a $1 billion patent infringement award in favor of Apple Inc. of lying about his past involvement in litigation and past ties to Samsung’s law firm, saying the jury verdict must be scrapped in favor of a new trial.


